Validation of a Test for Fetal Malformations

• ClinicalTrials.gov Identifier: NCT02965287
• Recruitment Status: Completed
• First Posted: November 16, 2016
• Last Update Posted: March 22, 2018
• Sponsor: Theoreo Srl
• Collaborators: Auckland UniServices Ltd.; Massachusetts General Hospital
• Information provided by (Responsible Party): Theoreo Srl

Study Description

Brief Summary:

The investigators have developed a diagnostic test for the evaluation of the presence of fetal malformations through metabolomic analysis of maternal peripheral blood serum by chromatographic techniques and mass spectrometry, and subsequent mathematical modeling analysis of the data by means of multivariate mathematical models specifically developed for this purpose. The study aims at determining the performance parameters (specificity, sensibility, positive predictive value (PPN), negative predictive value (NPV), etc.) of the test and its applicability. To do this, the investigators will use the serum samples of the patients enrolled in New Zealand in the SCOPE Study (www.scopestudy.net), an international study conducted between years 2004-2008.

Condition or disease	Intervention/treatment
Fetal Anomaly	Other: Serum metabolomics profiling

Detailed Description:

The test has been developed in a case-control study. In this clinical trial the investigators will test it in a large cohort that is likely to resemble a real population. The purpose of validation is to see if the test is able to recognize the few malformed fetuses in the entire population and especially its specificity in real conditions. In addition, the investigators will check whether particular maternal conditions (such as preeclampsia, gestational diabetes, etc.) or fetal conditions (Small for gestational age, Large for gestational age, etc.) affect the test results.

Study Design

• Study Type: Observational
• Estimated Enrollment: 1943 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Blind Validation of a Metabolomics Based Test for the Non-invasive Screening of Fetal Malformations
• Study Start Date: September 2016
• Actual Primary Completion Date: December 2017
• Actual Study Completion Date: December 2017

Groups and Cohorts

Group/Cohort	Intervention/treatment
19-21 weeks' gestation; The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study. All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose.	Other: Serum metabolomics profiling; The serum samples will be used to get a metabolomic profile
14-16 weeks' gestation; Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.	Other: Serum metabolomics profiling; The serum samples will be used to get a metabolomic profile

Outcome Measures

Primary Outcome Measures :

1. Diagnostic test performance evaluation in dichotomic classification at 19-21 weeks' gestation [ Time Frame: 6 months ]
   Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of a malformed fetus through the analysis of a serum sample from a mother at 19-21 weeks' gestation
2. Diagnostic test performance evaluation in the individuation of the exact diagnosis of fetal malformation at 19-21 weeks' gestation [ Time Frame: 6 months ]
   Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of the type of malformation through the analysis of a serum sample from a mother at 19-21 weeks' gestation

Secondary Outcome Measures :

1. Diagnostic test performance evaluation in dichotomic classification at 14-16 weeks gestation [ Time Frame: 6 months ]
   Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of a malformed fetus through the analysis of a serum sample from a mother at 19-21 weeks' gestation
2. Diagnostic test performance evaluation in the individuation of the exact diagnosis of fetal malformation at 14-16 weeks gestation [ Time Frame: 6 months ]
   Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) in the identification of the type of malformation through the analysis of a serum sample from a mother at 14-16 weeks gestation

Biospecimen Retention:   Samples Without DNA

Serum samples

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

The study population is the ones selected by the SCOPE Study in New Zealand

Criteria

Inclusion criteria were the ones designed by SCOPE Study:

- Nulliparous women, with a singleton pregnancy, between 14wks, 0 days and 16wks, 6 days gestation who give informed consent to participate in SCOPE.

Exclusion criteria were the ones designed by SCOPE Study:

• Unsure of last menstrual period (LMP)
• Unwilling to have ultrasound scan at ≤20 weeks
• ≥3 miscarriages
• ≥3 terminations
• Essential hypertension treated pre-pregnancy
• Moderate-severe hypertension at booking ≥160/100 mmHg
• Diabetes
• Renal disease
• Systemic lupus erythematosus
• Anti-phospholipid syndrome
• Sickle cell disease
• HIV positive
• Major uterine anomaly
• Cervical suture
• Knife cone biopsy
• Ruptured membranes now
• Long term steroids
• Treatment low-dose aspirin
• Treatment calcium (>1g/24h)
• Treatment eicosapentanoic acid (fish oil)
• Treatment vitamin C ≥1000 mg & Vit E ≥400 iu
• Treatment heparin/low molecular weight heparin

Contacts and Locations

Locations

Italy

Theoreo srl

Montecorvino Pugliano, Salerno, Italy, 84090

Sponsors and Collaborators

Theoreo Srl

Auckland UniServices Ltd.

Massachusetts General Hospital

Investigators

• Principal Investigator: Jacopo Troisi, Dr.; CEO

More Information

Publications:

McCowan LM, Thompson JM, Taylor RS, North RA, Poston L, Baker PN, Myers J, Roberts CT, Dekker GA, Simpson NA, Walker JJ, Kenny LC; SCOPE Consortium. Clinical prediction in early pregnancy of infants small for gestational age by customised birthweight centiles: findings from a healthy nulliparous cohort. PLoS One. 2013 Aug 5;8(8):e70917. doi: 10.1371/journal.pone.0070917. Print 2013.

• Responsible Party: Theoreo Srl
• ClinicalTrials.gov Identifier: NCT02965287
• Other Study ID Numbers: MV-01
• First Posted: November 16, 2016
• Last Update Posted: March 22, 2018
• Last Verified: October 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Test validation of the screening technique will be conducted blinded. The investigators will have access only to the serum samples identified by their unique ID. At the end of the analytical phase, the database containing results will be locked. The database will be transferred to an independent investigator (Prof. Alessio Fasano at Mass General Hospital for Children, Boston, USA) for data analysis. At the same time, information related to pregnancy outcomes (in terms of presence or absence of fetal anomaly) will be transferred from the University of Auckland to the Mass General Hospital for Children, which will provide the blind break and will procced to the estimation of the test performance.

Additional relevant MeSH terms:

Congenital Abnormalities